EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Value of TERT promoter mutations for early outcomes in papillary thyroid cancer

Min Jhi Kim iD, Daham Kim iD, Hye Sun Lee, Se Hee Park, Eun Jin Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Kee-Hyun Nam iD

Endocrine-Related Cancer · 2026

DOI: 10.1530/erc-25-0424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Min Jhi Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, CHA Ilsan Medical Center, CHA University School of Medicine , Goyang-si, Gyeonggi-do, South Korea. Hauptthemen laut MEDLINE: Telomerase, Thyroid Neoplasms, Promoter Regions, Genetic, Thyroid Cancer, Papillary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Telomerase reverse transcriptase (TERT) promoter mutations are associated with aggressive clinicopathological features of papillary thyroid cancer (PTC). However, their independent prognostic value remains unclear. This study aimed to evaluate the prognostic significance of TERT promoter mutations (TPMs) in predicting early treatment outcomes and event-free survival (EFS) in patients with PTC. We retrospectively analyzed a prospective cohort; patients underwent surgery at a single tertiary referral center between 2019 and 2022. Patients underwent thyroidectomy, selective postoperative radioactive iodine ablation, and levothyroxine suppression therapy. Propensity score matching (PSM, 1:1) was applied to adjust for baseline clinicopathological differences. Of 10,642 patients with available molecular data, 115 (1.1%) harbored TPMs. After PSM, 90 matched pairs of patients with TERT-wild-type and TERT-mutant tumors were analyzed. Early treatment responses at 1 and 2 years post-treatment and EFS were evaluated. Early treatment responses did not differ significantly between groups at 1 year (P = 0.212) and 2 years (P = 0.571). However, patients with TERT-mutant tumors had fewer excellent responses and higher rates of structural incomplete response. During follow-up, the TERT-mutant group experienced more recurrences and one disease-specific death. Cumulative EFS was significantly poorer in the TERT-mutant group than in the TERT-wild-type group (P = 0.022). Despite their low prevalence, TPMs were independently associated with adverse oncological outcomes, including higher rates of recurrence and mortality. TPMs may serve as valuable prognostic markers for early risk stratification in PTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseThyroid NeoplasmsPromoter Regions, GeneticThyroid Cancer, PapillaryHumansFemaleMutationMiddle AgedMaleAdultPrognosisRetrospective Studies

Stichwörter der Autor:innen

TERT promoter mutationevent-free survivalpapillary thyroid cancerprognostic factorpropensity score matching

Substanzen

TelomeraseTERT protein, human

Autor:innen und Institutionen

  • Department of Surgery, CHA Ilsan Medical Center, CHA University School of Medicine , Goyang-si, Gyeonggi-do, South Korea.
  • Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine , Seoul, South Korea.
  • Biostatistics Collaboration Unit, Yonsei University College of Medicine , Seoul, South Korea.
  • Department of Surgery, Yonsei University College of Medicine , Seoul, South Korea.

ORCID-Profile: Min Jhi Kim, Daham Kim, Kee-Hyun Nam

Zitieren

APA

Kim, M. J., Kim, D., Lee, H. S., Park, S. H., Kim, E. J., Kim, J. K., Kang, S. W., Lee, J., Jeong, J. J., Chung, W. Y., & Nam, K. H. (2026). Value of TERT promoter mutations for early outcomes in papillary thyroid cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0424

Vancouver

Kim MJ, Kim D, Lee HS, Park SH, Kim EJ, Kim JK, et al. Value of TERT promoter mutations for early outcomes in papillary thyroid cancer. Endocrine-Related Cancer. 2026. doi:10.1530/erc-25-0424

BibTeX
@article{Kim2026,
  author = {Kim, Min Jhi and Kim, Daham and Lee, Hye Sun and Park, Se Hee and Kim, Eun Jin and Kim, Jin Kyong and Kang, Sang-Wook and Lee, Jandee and Jeong, Jong Ju and Chung, Woong Youn and Nam, Kee-Hyun},
  title = {Value of TERT promoter mutations for early outcomes in papillary thyroid cancer},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  doi = {10.1530/erc-25-0424}
}
Kostenlos starten →